Vamstar lands £900,000 UK grant to show drug makers what payers will accept
What's the deal? VamstarDealroom has a profile for this one. Try Dealroom →, a London-based life sciences AI company, has won £900,000 (about $1.19 million) through Innovate UK's Sovereign AI programmeDealroom has a profile for this one. Try Dealroom →. The grant funds a UK-owned platform that helps health technology developers anticipate payer requirements and predict launch outcomes before trial protocols are locked in.
What's the endgame? The company's agentic AI connects clinical trial evidence, health-economic modelling, and real-world pricing data in one system. Development teams can see which evidence payers will expect, and what price that evidence supports, while design choices are still open.
Why now? Evidence strategy and pricing assumptions are fixed at trial design, often years before bodies such as the National Institute for Health and Care Excellence (NICE) decide whether the evidence justifies the price. By the time a payer finds a gap, the trial can no longer change.
"The industry spends years generating evidence and only learns at the end whether payers will accept it. We are reversing that order," said Praful Mehta, chief executive officer and co-founder of Vamstar.
What's next? The award moves the technology from a validated proof of concept to a working demonstrator over the next 12 months. It will extend coverage across six therapeutic areas and run at scale as a cloud service, offered to pharmaceutical, biotech, and medtech companies, NHS bodies, and healthcare innovators.
An earlier Innovate UK-funded proof of concept showed that evidence retrieval and health-economic modelling could be automated with results consistent with published NICE outcomes, reaching over 90% reproducibility. Every output links back to its source evidence, and the system runs on UK infrastructure.
The signal: The grant sits among the larger awards in its cohort — Innovate UK selected only the top 1% of projects for the Sovereign AI programme. It reflects a push to bring payer intelligence earlier into drug and device development, in a sector where global pharmaceutical R&D runs past £200 billion a year and most late-stage candidates never reach commercial viability.
Read more: pressat.co.uk
Image credit: Vamstar
